Literature DB >> 1583066

Capture of recombinant ricin A chain by a bispecific anti-RTA:anti-CEA monoclonal antibody pre-targeted to a human gastric carcinoma xenograft in nude mice.

M V Pimm1, R A Robins, R W Baldwin.   

Abstract

A bispecific antibody against carcinoembryonic antigen (CEA) and ricin A chain has been shown to localise in a CEA-producing human tumour xenograft. When labelled recombinant ricin A chain was subsequently injected there was uptake into tumours, indicating that this bispecific antibody can capture or carry toxin into tumour deposits.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1583066     DOI： 10.1007/bf01294441

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


  15 in total

1.  Cooperative mixtures of bispecific F(ab')2 antibodies for delivering saporin to lymphoma in vitro and in vivo.

Authors:  R R French; A E Courtenay; S Ingamells; G T Stevenson; M J Glennie
Journal:  Cancer Res       Date:  1991-05-01       Impact factor: 12.701

2.  Bispecific antibody that binds carcinoembryonic antigen and ricin toxin A chain cytotoxic for gastrointestinal tract tumor cells.

Authors:  R A Robins; M J Embleton; M V Pimm; D S Betts; A Charleston; A J Markham; R W Baldwin
Journal:  J Natl Cancer Inst       Date:  1990-08-01       Impact factor: 13.506

Review 3.  Bispecific antibody: a tool for diagnosis and treatment of disease.

Authors:  S Songsivilai; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

4.  Localization of an anti-CEA monoclonal antibody in colo-rectal carcinoma xenografts.

Authors:  M V Pimm; N C Armitage; A C Perkins; W Smith; R W Baldwin
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

5.  Bispecific F(ab' gamma)2 antibody for the delivery of saporin in the treatment of lymphoma.

Authors:  M J Glennie; D M Brennand; F Bryden; H M McBride; F Stirpe; A T Worth; G T Stevenson
Journal:  J Immunol       Date:  1988-11-15       Impact factor: 5.422

6.  Specific in vitro and in vivo drug localisation to tumour cells using a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids.

Authors:  J R Corvalan; W Smith; V A Gore; D R Brandon
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

7.  Influence of recombinant tumour necrosis factor alpha on blood flow and antibody localisation in human tumour xenografts in nude mice.

Authors:  M V Pimm; S J Gribben; T M Morris
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

8.  Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal-cell carcinoma xenografts: relative effects of size and affinity.

Authors:  J van Dijk; S T Zegveld; G J Fleuren; S O Warnaar
Journal:  Int J Cancer       Date:  1991-07-09       Impact factor: 7.396

9.  Recombinant ricin toxin A chain cytotoxicity against carcinoembryonic antigen expressing tumour cells mediated by a bispecific monoclonal antibody and its potentiation by ricin toxin B chain.

Authors:  M J Embleton; A Charleston; R A Robins; M V Pimm; R W Baldwin
Journal:  Br J Cancer       Date:  1991-05       Impact factor: 7.640

10.  A bispecific monoclonal antibody against methotrexate and a human tumour associated antigen augments cytotoxicity of methotrexate-carrier conjugate.

Authors:  M V Pimm; R A Robins; M J Embleton; E Jacobs; A J Markham; A Charleston; R W Baldwin
Journal:  Br J Cancer       Date:  1990-04       Impact factor: 7.640
View more
  1 in total

1.  Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA.

Authors:  S A Watson; T M Morris; H M Collins; L J Bawden; K Hawkins; E A Bone
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.